Drug Development, Protocols

Protocols: Leap reverse merges with a failing Macrocure; Ferring bags rights to PhIII sciatica drug

Leap Therapeutics is reverse merging its way onto the stock exchange. Leap signed a deal with Macrocure to merge operations, with HealthCare Ventures investing an additional $10 million into their immune-oncology research work. Macrocure, a regenerative med company which has been struggling in the wake of two big Phase III failures, gets 31% of the new company.

Switzerland’s Ferring Pharmaceuticals inked a deal with Seikagaku Corporation granting Ferring the exclusive worldwide rights (excluding Japan) to SI-6603 (condoliase), a chemonucleolytic product in Phase III development for the treatment of radicular leg pain (conditions that include sciatica) due to lumbar disc herniation.

India’s Mitra Biotech has raised $27.4 million from a group of investors which includes Boston-based RA Capital. Mitra has been developing new tech to predict a patient’s response to personalized cancer drugs.

Get Endpoints News in your inbox

Daily update for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News every day. Free subscription.


Subscribe to Endpoints

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy